These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 27232927)
21. Levosimendan: The current situation and new prospects. Moreno N; Tavares-Silva M; Lourenço AP; Oliveira-Pinto J; Henriques-Coelho T; Leite-Moreira AF Rev Port Cardiol; 2014 Dec; 33(12):795-800. PubMed ID: 25459636 [TBL] [Abstract][Full Text] [Related]
22. [Levosimendan, a revolution in the world of inotropic agents?]. Bonnefoy E; Trindade PT Rev Med Suisse; 2005 May; 1(21):1425-6, 1428-9. PubMed ID: 15997981 [TBL] [Abstract][Full Text] [Related]
23. Considerations on the efficacy and safety of levosimendan in ischemic heart failure. Nieminen MS; Sandell EP Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369 [TBL] [Abstract][Full Text] [Related]
24. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226 [TBL] [Abstract][Full Text] [Related]
30. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Cleland JG; Nikitin N; McGowan J Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409 [TBL] [Abstract][Full Text] [Related]
31. Levosimendan meta-analyses: Is there a pattern in the effect on mortality? Pollesello P; Parissis J; Kivikko M; Harjola VP Int J Cardiol; 2016 Apr; 209():77-83. PubMed ID: 26882190 [TBL] [Abstract][Full Text] [Related]
32. The clinical effects of levosimendan are not attenuated by sulfonylureas. Kivikko M; Nieminen MS; Pollesello P; Pohjanjousi P; Colucci WS; Teerlink JR; Mebazaa A Scand Cardiovasc J; 2012 Dec; 46(6):330-8. PubMed ID: 22928945 [TBL] [Abstract][Full Text] [Related]
33. Levosimendan: from basic science to clinical trials. Rognoni A; Lupi A; Lazzero M; Bongo AS; Rognoni G Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):9-15. PubMed ID: 21208157 [TBL] [Abstract][Full Text] [Related]
34. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy. Guarracino F; Cariello C; Danella A; Doroni L; Lapolla F; Stefani M; Baldassarri R; Vullo C Acta Anaesthesiol Scand; 2007 Oct; 51(9):1217-24. PubMed ID: 17850562 [TBL] [Abstract][Full Text] [Related]
35. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure. Duygu H; Ozerkan F; Nalbantgil S; Zoghi M; Akilli A; Akin M; Nazli C; Ergene O Int J Cardiol; 2008 Jan; 123(2):201-3. PubMed ID: 17316845 [TBL] [Abstract][Full Text] [Related]
37. Randomized clinical trials with levosimendan. Mebazaa A; Barraud D; Welschbillig S Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826 [TBL] [Abstract][Full Text] [Related]
38. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656 [TBL] [Abstract][Full Text] [Related]
39. Role of levosimendan in sepsis and septic shock. Pinto BB; Rehberg S; Ertmer C; Westphal M Curr Opin Anaesthesiol; 2008 Apr; 21(2):168-77. PubMed ID: 18443483 [TBL] [Abstract][Full Text] [Related]